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Abstract
Introduction: The diagnostic category of follicular lesion of undetermined significance (FLUS) was intended to allow selection of cases 
with low risk of malignancy from all smears with indeterminate, suspicious cytology (ISC), which can potentially take advantage from 
repeat fine-needle aspiration (rFNA).
Aim of the study was a comparison of the risk of malignancy related to FLUS nodules and other nodules with ISC: suspected follicular 
neoplasm (SFN) and suspected malignancy (SM), as well as analysis of the usefulness of assessing ultrasonographic malignancy risk 
features (UMRF) in nodules with ISC.
Material and methods: We analysed UMRF, rFNA, and results of histopathological examination (H) in 441 FLUS, 135 SFN, and 72 SM nodules. 
Results: The frequency of exposing cancer in H in FLUS nodules was 5.9%, and when cytological follow up was also included it was 2.9%. 
rFNAs made the diagnosis more precise in 72.7% of FLUS, and in 5.2% it was diagnosis/suspicion of cancer. The incidence of cancer in SFN 
nodules was 8.2%, in SM nodules with suspicion of papillary cancer — 61.1%, and in nodules with suspicion of other or unspecified 
malignancy — 53.8% (p < 0.0001 FLUS vs. both groups). 
The presence of calcifications is the only independent UMRF for nodules with ISC (OR 4.7). Features of importance are also microcalcifica-
tions (OR 3.8), especially in the SM group, and taller-than-wide-shape (OR 2.2). FLUS and SFN nodules are characterised by particularly 
low value of assessing suspicious margins; analysis of hypoechogenicity is of low value in SFN nodules, like suspected vascularisation 
in SFN and SM nodules.
Conclusions: The risk of cancer in FLUS and SFN nodules is lower than in SM nodules. rFNAs of FLUS nodules make the diagnosis more 
precise in more than 70% of cases and are effective in revealing cancers. UMRFs present variable diagnostic value depending on the 
subcategory of ISC. (Endokrynol Pol 2016; 67 (1):  23–34)
Key words: thyroid cancer; FNA; FLUS
Streszczenie
Wstęp: Rozpoznanie zmiana pęcherzykowa bliżej nieokreślona (FLUS) miało wyodrębnić spośród rozmazów z niejednoznaczną, podej-
rzaną cytologią (ISC) przypadki z niskim ryzykiem złośliwości i potencjalną korzyścią z wykonania powtórnej FNA (rFNA).
Celem pracy było porównanie ryzyka złośliwości guzków FLUS i innych guzków z ISC: podejrzenie nowotworu pęcherzykowego (SFN) 
i podejrzenie złośliwości (SM) oraz analiza przydatności oceny ultrasonograficznych cech ryzyka złośliwości (UMRF) w guzkach z ISC.
Materiał i metody: Analizowano UMRF, rFNA i wyniki badania histopatologicznego (H) 441 guzków FLUS, 135 SFN i 72 SM. 
Wyniki: Częstość ujawniania raka w H w guzkach FLUS wynosiła 5,9%, a uwzględniając także cytologiczny follow up 2,9%. rFNAs uściśliły 
rozpoznanie w 72,7% guzków FLUS, w 5,2% ich wynik zawierał rozpoznanie/podejrzenie raka. Częstość raka w guzkach SFN wynosiła 8,2%, 
w guzkach SM z podejrzeniem raka brodawkowatego 61,1%, a z podejrzeniem innego nowotworu złośliwego lub bez określenia jego 
typu 53,8% (p < 0,0001 vs. FLUS w obu przypadkach). 
Obecność zwapnień jest jedyną niezależną UMRF dla guzków z kategorii ISC (OR 4,7). Ponadto znaczenie mają ocena mikrozwapnień (OR 3,8), 
szczególnie w grupie SM, i podejrzanego kształtu (OR 2,2). W grupach FLUS i SFN szczególnie niską wartość ma ocena podejrzanych 
granic, ponadto w grupie SFN analiza hipoechogeniczności, a w grupie SFN i SM — podejrzanego unaczynienia. 
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and the incidence of cancer among nodules with such 
diagnosis would not exceed 15%. Another assump-
tion was that FLUS diagnosis would not be a direct 
indication for surgical treatment, in contrast to other 
ISC categories (SFN and SM). However, numerous re-
ports indicate that FLUS may be related to higher than 
assumed risk of malignancy [7–14]. It is also unclear 
whether implementation of the new FLUS category 
does not significantly affect the malignancy risk related 
to other ISC categories (SFN and SM). That risk was as-
sumed for SFN category as 5–20% and for SM category 
— 30–50%, according to Polish Recommendations [6]. 
Thus, the aim of the paper was to determine the actual 
risk of malignancy in the case of FLUS diagnosis and to 
compare it to the cancer risk in cases of SFN and SM, as 
assessed by analysis of repeat FNA and postoperative 
histopathological examinations. An additional aim was 
the comparison of ultrasonographic characteristics of 
FLUS, SFN, and SM nodules in relation to the final 
histopathological diagnosis.
Material and methods
At the first step all FNA outcomes were selected, which 
had been classified as FLUS, SFN, or SM category in the 
period between May 2010 and May 2015. The patients 
diagnosed for suspicion of cancer recurrence were 
excluded from the analysis. 
Then the results of repeat FNA (rFNA) of FLUS 
nodules were analysed. The frequency was determined 
of formulation of particular diagnostic categories 
included in the current classification: non-diagnostic 
(ND), benign lesion (BL), FLUS, SFN, SM, and malig-
nant neoplasm (MN). Additionally, the frequency was 
assessed of results indicating the necessity for surgical 
treatment (SFN, SM, and MN) as well as of BL outcome 
— suggesting conservative treatment. 
For the next step the results of postoperative histo-
pathological examinations were analysed in patients 
treated surgically. The incidence of cancer in FLUS 
nodules was compared between patients operated after 
rFNA (in relation to the final cytological diagnosis) and 
patients subjected directly to the surgical treatment 
(without rFNA). Also, the incidence of cancer revealed 
by histopathological examination was determined in 
nodules diagnosed cytologically as SFN or SM. 
Introduction
Results of fine-needle aspiration biopsy (FNA) of the 
thyroid equivocal in respect to diagnosis or exclusion 
of cancer constitute a significant problem in clinical 
practice. They include mainly follicular lesions (FL). In 
such cases the routine cytological examination does not 
allow us to distinguish benign from malignant nodules, 
and the cytological result indicates only suspicious 
for follicular neoplasm (SFN) nodules. Indeterminate 
cytology may also be a consequence of the presence in 
a smear of features typical of thyroid cancer, but their 
degree is insufficient for unequivocal diagnosis. In such 
case the result indicates a suspicious of malignancy 
(SM) nodule [1].
Until recently, indeterminate, suspicious cytology 
(ISC) was considered as an indication for surgical 
treatment, which could solve diagnostic uncertainty. 
But the high variability of the cancer risk (between 
5 and 30% for FL and from 30 to 70% for SM) related 
to such diagnoses raised marked clinical doubts [2–3]. 
The problem was aggravated by the lack of uniform 
formulation of diagnostic conclusion in such cases. 
Thus, the attempt to improve classification of cytologi-
cal results undertaken by the National Cancer Institute 
(NCI) in 2008 was accepted with much hope by centres 
focused on diagnostics of the thyroid nodules [4–5]. In 
Poland the new classification of thyroid biopsy results, 
based on NCI proposal, has been in full operation for 
five years [6]. The classification introduced the new 
subgroup of the results within ISC “follicular lesion 
of undetermined significance” (FLUS). The goal of 
that modification was to delineate FL with low malig-
nancy risk, in which it is justified to perform repeat 
FNA within 6 to 18 months in order to obtain more 
precise diagnosis. That additional diagnostic category 
was meant to be formulated mainly when there were 
features of both benign lesion and follicular neoplasm 
coexisting in a smear, and in that way it was adopted 
into Polish recommendations for diagnostics of the 
thyroid nodules [6]. However, the definition of FLUS 
adopted by the NCI is wider. It includes also the bor-
derline results when characteristic features of benign 
and malignant lesions coexist in a smear and the cel-
lularity of aspirate is scant [4–5]. It was assumed that 
FLUS diagnosis should be rarely formulated (< 7%) 
Wnioski Ryzyko raka w guzkach FLUS i SFN jest niższe niż w kategorii SM. rFNA guzków FLUS uściśla rozpoznanie w ponad 70% 
przypadków i jest skuteczna w ujawnianiu raków. UMRF mają zróżnicowaną wartość diagnostyczną w zależności od podkategorii ISC. 
(Endokrynol Pol 2016; 67 (1): 23–34)
Słowa kluczowe: rak tarczycy; biopsja aspiracyjna cienkoigłowa; zmiana pęcherzykowa bliżej nieokreślona
This work was supported by the Medical University of Lodz (grant number 502-03/1-153-05/502-14-172) — granted to MWN.
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Finally, the size and ultrasonographic features of 
FLUS, SFN, and SM nodules were compared in relation 
to the final histopathological diagnosis: benign nodule 
vs. malignant neoplasm. The presence of the following 
ultrasonographic malignancy risk features (UMRF) were 
assessed: 1) hypoechoic (compared with the surrounding 
thyroid or strap muscles) and solid ( < 10% cystic) echo-
structure, 2) calcifications with separate consideration 
for microcalcifications, 3) irregular or blurred margins, 
4) more-tall-than-wide shape (measured in a transverse 
view), and 5) chaotic intranodular vascular spots. Also, 
the occurrence was analysed of: 1) > 1 UMRFs, 2) pres-
ence of at least 1 UMRF recognised as significant in 
examined ISC nodules on the basis of logistic regression 
analysis, 3) presence of hypoechoic solid nodule with at 
least one other risk feature (with exception of suspicious 
vascularisation) — which is the criterion for high risk of 
malignancy adopted in the new American Thyroid As-
sociation (ATA) recommendations [15], and 4) presence 
of a nodule with at least one risk feature enumerated by 
ATA independently on its hypoechogenicity. 
The FNAs were carried out in patients referred by 
endocrinologists from outpatient clinics. All the biopsies 
were US-guided. The US examinations were performed 
with the use of two high-resolution sonographs with 
a 7.5–13 MHz linear transducer and power Doppler 
capability, before September 2011 (Siemens Elegra Ad-
vanced, Siemens Medical Systems, Inc., Issaquah, WA, 
USA and then Aloka Prosound Alpha 7, ALOKA Co. 
Ltd., Tokyo, Japan). FNAs were performed on nodules 
with a diameter of at least 5 mm, which were palpable 
or had at least one malignancy risk factor (ultrasono-
graphic or clinical). Smears were fixed in 95% ethanol 
solution and stained with haematoxylin and eosin. 
A detailed description of the FNA procedure was pre-
sented in our earlier work [16–17]. 
Specimens showing a population of thyroid folli-
cular cells (TFC) arranged in three-dimensional sheets, 
groups, and microfollicles (sometimes with nuclear 
overlapping and crowding) with scant or no colloid 
in background, or containing single cell population of 
oncocytic TFC arranged in sheets, and groups were 
classified as SFN or SFN oxyphilic type (SFN-O), respec-
tively. A diagnosis of FLUS (or FLUS-O respectively) 
was made when the specimen showed features of 
both benign lesion and follicular neoplasm or showed 
low cellularity with the presence of architectural or 
so-called nuclear atypia. The SM category included 
nodules, aspirates from which showed morphological 
features of malignant neoplasm, but they did not meet 
all criteria necessary for such diagnosis. In that category 
the subgroup of nodules raising suspicion of papillary 
cancer (SM-pap), as well as the subgroup with features 
suggesting other malignant neoplasm or not allowing 
to specify its histogenesis (SM-non-pap), were created. 
Another analysed subgroup included very scant aspi-
rates but with single cancer features and a cytological 
result that showed a low diagnostic value of aspirates 
and necessity of performing repeat FNA as soon as 
possible (SM-low diagnostic).
Surgical thyroidectomy specimens were processed 
by standard procedures. If necessary, immunohisto-
chemical analysis was applied. Histopathological results 
were formulated according to the WHO Histological 
Classification of Thyroid Tumours. 
Continuous variables (like the age of patients) were 
analysed with ANOVA and Newman–Keuls test. The 
comparison of frequency distributions was performed 
with chi2 test (or with Yates corrected chi2 test). As-
sociations between US features and malignancy were 
evaluated by using logistic regression analysis, and 
odds ratios (OR) with relative 95% confidence intervals 
(95% CI) were calculated to determine the relevance of 
all potential predictors of outcome. Sensitivity (SEN), 
specificity (SPC), positive predictive value (PPV), and 
negative predictive value (NPV) were analysed based 
on established UMRF sets. The value of 0.05 was as-
sumed as the level of significance. 
The study design was approved by the Local Bioeth-
ics Committee. 
Results
Table I shows the characteristics of patients with FNA 
results classified into particular ISC categories. Diag-
noses of FLUS/FLUS-O were formulated in the case of 
753 nodules. That category constituted between 3.7% and 
5.1% of all FNA results in subsequent years. The results 
belonging to the SFN/SFN-O category were formulated 
Table I. Characteristics of the patients in analysed groups of 
cytological diagnoses
Tabela I. Charakterystyka pacjentów w poszczególnych 
grupach rozpoznań cytologicznych
FLUS/FLUS-O SFN/SFN-O SM
Number of patients 722 181 85
Age — mean ± SD 
(years)
59.7 ± 13.4 58.2 ± 15.5 57.7 ± 19.7
Gender
Females
Males
653 (90.4%) 
69 (9.6%)
155 (85.6%) 
26 (14.4%)
71 (83.5%)
14 (16.5%)a
Number of nodules 753 183 85
Volume of nodules 
mean ± SD [cm3]
5.5 ± 12.8 5.8 ± 11.9 6.4 ± 10.5
apercentage of males p < 0.05 vs. FLUS/FLUS-O. FLUS — follicular lesion of 
undetermined significance; SFN — suspicious for follicular neoplasm; SM — 
suspicious for malignancy
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in 183 nodules, with frequency between 1.0 and 1.5%. 
FNA results categorised as SM constituted less than 
1% of all diagnoses, and were observed in 85 patients. 
No significant differences were noted between those 
categories in the mean age of patients or the mean 
volume of nodules. The percentage of males in the SM 
group was significantly higher than in the FLUS/FLUS-
O group (16.5 vs. 9.6, p < 0.05).
Figures 1–3 show data on cytological and histo-
pathological follow up of the nodules of the examined 
ISC groups. In total, the follow up included 441 nod-
ules of FLUS/FLUS-O category (431 and 10 nodules, 
respectively), 135 nodules of SFN/SFN-O category 
(70 and 65, respectively), and 72 nodules of SM cat-
egory (43 SM-pap, 13 SM-non-pap, and 16 SM-low 
diagnostic). 
Table II shows the results of rFNA of nodules diag-
nosed as FLUS/FLUS-O in the first cytology, and Table 
III summarises final cytological diagnoses of those 
nodules. Eventually rFNA allowed us to obtain more 
precise diagnosis in 197 out of 271 (72.7%) nodules, 
(in 176 — 64.9% —cases first rFNA allowed the for-
 753 nodules
 (734 FLUS & 19 FLUS-O)  
 in 722 patients  
312 nodules
(303 FLUS & 9 FLUS-O)
in 291 patients
Without follow up
Repeat FNAs 32 nodules
(31 FLUS & 1 FLUS-O)
in 30 patients
Follow-up for 441 nodules
(431 FLUS & 10 FLUS-O)
 in 431 patients
271 nodules
(266 FLUS & 5FLUS-O)
 in 269 patients
202 nodules
(196 FLUS & 6 FLUS-O)
in 192 patientsSurgery after repeat FNA
Surgery
Figure 1. Characteristics of analysed FLUS/FLUS-O nodules
Rycina 1. Charakterystyka badanych guzków FLUS/FLUS-O
183 nodules   
 (90 SFN & 93 SFN-O)  
 in 181 patients
48 nodules
(20 SFN & 28 SFN-O)
in 46 patients
Without follow up
Repeat FNAs 
1 SFN-O nodule
Follow-up for 135 nodules
(70 SFN & 65 SFN-O)
in 135 patients
14 nodules
(5 SFN & 9 SFN-O) 
in 14 patients
122 nodules
(65 SFN & 57 SFN-O)
in 122 patientsSurgery after repeat FNA
Surgery
Figure 2. Characteristics of analysed SFN/SFN-O nodules
Rycina 2. Charakterystyka badanych guzków SFN/SFN-O
85 nodules
(52 SM-pap, 16 SM-non-pap, 
17 SM-low diagnostic) 
 in 85 patients
13 nodule
(9 SM-pap, 3 SM-non-pap
1 SM-low diagnostic)
 in 13 patients
Without follow up
Repeat FNAs 
2 SM-low diagnostic
Follow-up for 72 nodules
 (43 SM-pap, 13 SM-non-pap, 16 SM-low diagnostic)
 in 72 patients
12 nodules 
SM-low diagnostic 
 in 12 patients
62 nodules
(43 SM-pap, 13 SM-non-pap,
6 SM-low diagnostic) 
in 62 patients
Surgery after repeat FNA
Surgery
Figure 3. Characteristics of analysed SM nodules
Rycina 3. Charakterystyka badanych guzków SM
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mulation of a more precise result). The BL diagnosis 
was formulated in 183 cases (67.5% of FLUS/FLUS-O 
nodules examined with rFNA), SFN/SFN-O — in 
6 cases (2.2%), SM — also in 6 cases (2.2%), and MN 
in 2 cases (0.7%). In the case of 74 (27.3%) nodules 
FLUS/FLUS-O was sustained or rFNA did not change 
the diagnosis because of a lack of cellular material. 
All 14 (5.2%) diagnoses related to the risk of malig-
nancy higher than that of FLUS/FLUS-O, i.e. SFN, 
SM, and MN, were formulated in two first rFNA (10 
in the second FNA and 4 in the third FNA) (Table II). 
Only one of those nodules increased its volume, but 
the increase was less than 50%.
Postoperative histopathological examination of 
FLUS/FLUS-O nodules revealed 12 (5.9%) thyroid can-
cers: 11 (5.6%) in FLUS nodules (10 papillary cancers, 
1 undifferentiated cancer) and 1 (16.7%) in FLUS-O 
nodule (follicular cancer of oxyphilic type) (Table IV). 
Additionally, in eight patients papillary cancers were 
revealed in other nodules: in seven cases the nodules 
were incidentaloma of several millimetres in diameter, 
and in one case the cancer was diagnosed with FNA in 
the other lobe of the thyroid. 
In the group of 30 patients with 32 FLUS/FLUS-O 
nodules operated after rFNA 6 cancers were found 
(18.8%); all of them were diagnosed with rFNA (di-
agnoses of MN or SM). In the group of 162 patients 
operated without preceding rFNA cancers were found 
less frequently — in 6 out of 170 (3.5%, p < 0.001) 
Table II. Results of subsequent FNA in patients with cytological 
diagnosis of FLUS/FLUS-O, SFN/SFN-O, SM (the results of 
eventually operated patients are shown in parentheses)
Tabela II. Wyniki kolejnych FNA pacjentów z cytologicznym 
rozpoznaniem FLUS/FLUS-O, SFN/SFN-O, SM (wyniki osób 
następnie operowanych wskazane w nawiasach)
1. FNA 2. FNA 3. FNA 4. FNA 5. FNA 6. FNA
FLUS — 266 ND-36 ND-5 (1) ND-1
BL-2 ND-1
BL-12 ND-1 (1)
BL-2
FLUS-1 FLUS-1
FLUS-6 (1)
SFN-1 (1)
SM-2 (2)
ZŁ-163 (7) ND-3 BL-1 BL-1
BL-32 (1)* BL-8 BL-1 BL-1
FLUS-2 BL-1
FLUS-8 (1) BL-3
FLUS-56 (9) BL-13 BL-3
FLUS-4 FLUS-1
FLUS-5 BL-1
SM-1 (1)
FLUS-O-2
SFN-4 (2)
SM-3 (2)
MN-2 (2)
FLUS-O — 5 ND-1
BL-3 BL-1 FLUS-O-1 BL-1
SFN-O-1 (1)
271 271 (23) 89 (8) 30 (1) 7 1
SFN — 5 ND-1 ND-1 BL-1
BL-2 FLUS-1
FLUS-2 BL-1
FLUS-1
SFN-O — 9 ND-1 SFN-O-1 (1)
BL-3 BL-2
FLUS-O-2
SFN-O-3 SFN-O-1
14 14 7 (1) 1
SM-low 
diagnostic
BL-9 (1)
FLUS-2 (1)
SM-pap-1
12 12 (2)
*MN in nodules other then previous FLUS. BL — benign lesion; FLUS — follicular lesion 
of undetermined significance; ND — non-diagnostic; MN — malignant neoplasm;  
SFN — suspicious for follicular neoplasm; SM — suspicious for malignancy
Table III. Final cytological diagnosis in repeat FNA (in the 
case of non-diagnostic aspiration the former FNA result was 
accepted)
Tabela III. Ostateczne rozpoznanie cytologiczne w powtórnych 
FNA (w przypadku wyniku niediagnostycznego przyjmowano 
wynik wcześniejszej FNA)
First FNA category Final cytological diagnosis
 — number (%)
FLUS — 266 ND — 13 (4.9%)
BL — 180 (67.7%)
FLUS/FLUS-O — 60 (22.6%)*
SFN — 5 (1.9%)
SM — 6 (2.2%)
MN — 2 (0.8%)
FLUS-O — 5 ND-1 (20.0%)
BL-3 (60.0%)
SFN-O — 1 (20.0%)
*including 2 cases of FLUS-O. BL — benign lesion; FLUS — follicular lesion of 
undetermined significance; MN — malignant neoplasm; ND — non-diagnostic; 
SFN — suspicious for follicular neoplasm; SM — suspicious for malignancy
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nodules. Considering both histopathological and 
cytological follow-up of FLUS/FLUS-O nodules, thy-
roid cancers were revealed in 13 out of 441 nodules 
(2.9%), including 12 out of 431 FLUS (2.8%) and 1 out 
of 10 FLUS-O (10.0%). Detailed analysis of cytologi-
cal reports with FLUS/FLUS-O in conclusion showed 
that cancers were diagnosed in 1 out of 3 (33.3%) 
nodules with single grooves or intranuclear vacuoles 
present in aspirate, in 5 out of 90 (5.5%) nodules with 
anisokaryosis of TFC in the smear, and in 6 out of 
109 (5.5%) nodules with monomorphic TFC with 
features of architectural atypia.
In SFN/SFN-O nodules thyroid cancers were 
found in postoperative histopathological examina-
tion in 10 out of 122 nodules (8.2%) (NS vs. FLUS), 
including 4 out of 65 (6.2%) SFN nodules (2 papillary 
cancers, 1 follicular cancer, 1 undifferentiated cancer) 
and in 6 out of 57 (10.5%) SFN-O nodules (1 papillary 
cancer and 5 follicular cancers, 2 of them of oxyphilic 
type) (Table IV). The result did not indicate higher 
risk of malignancy (SM or MN) in any of the rFNA of 
SFN/SFN-O nodules (Table II). Only one patient was 
operated after rFNA (which confirmed SFN-O), and 
in histopathological examination the hyperplastic 
nodule was found. Considering nodules followed 
up histopathologically or cytologically, thyroid can-
cers were found in 7.4% of cases — more frequently 
than in the FLUS/FLUS-O group (p < 0.05), in 4 out 
of 70 (5.7%) SFN nodules, and in 6 out of 65 (9.2%) 
SFN-O nodules. 
In the group of SM nodules thyroid cancers were 
revealed histopathologically in 30 out of 62 (48.4%) 
nodules, with similar frequency in SM-pap nodules 
— 51.1% (22 out of 43 nodules, papillary cancers 
only) and SM-non-pap nodules — 53.8% (7 out of 
13 nodules, 3 papillary cancers, 1 medullary cancer, 
1 adenoid cystic carcinoma, 2 malignant neoplasms of 
unclear histogenesis). No thyroid cancer was found in 
any of the 7 nodules of the SM-pap subgroup, in case 
of which the cytological report contained a commen-
tary indicating low cancer probability; after exclusion 
of those nodules the incidence of malignancy in the 
SM-pap subgroup was 61.1% (22 out of 36 nodules) 
(Table IV). In both mentioned SM subgroups (SM-pap 
and SM-non-pap) the incidence of cancer was higher 
than in the FLUS/FLUS-O and SFN/SFN-O group 
(p < 0.0001 in both cases). In the SM-low diagnostic 
subgroup cancer (papillary) was found in 1 out of 
6 (16.7%) nodules; 2 patients in that subgroup were 
operated after rFNA, the result of which corresponded 
to BL and FLUS, and histopathological examination 
confirmed benign lesion. rFNA was also performed 
in 12 non-operated patients — of SM-low diagnostic 
subgroup only: in one patient the result implying 
Table IV. Results of histopathological examinations of the thyroid in relation to the category of FNA result
Tabela IV. Wyniki badań histopatologicznych tarczycy w zależności od kategorii wyniku FNA
Category of FNA result
(number of nodules)
Result of histopathological examination
Benign nodule Malignant neoplasm
Non-neoplastic lesions Benign neoplasm
FLUS (196) 164 (83.7%) 21 (10.7%) 11 (5.6%)
FLUS-O (6) 5 (83.3%) 0 1 (16.7%)
FLUS/FLUS-O (202) 169 (83.7%) 21 (10.4%) 12 (5.9%)
190 (94.1%)
SFN (65) 53 (81.5%) 8 (12.3%) 4 (6.2%)
SFN-O (57) 43 (75.4%) 8 (14.0%) 6 (10.5%)
SFN/SFN-O (122) 96 (78.7%) 16 (13.1%) 10 (8.2%)
112 (91.8%)
SM-ca pap (43) 19 (44.2%) 2 (4.7%) 22 (51.1%)a, b
(22/36 — 61.1%)*)
SM-non-pap (13) 5 (38.5%) 1 (7.7%) 7 (53.8%)a, b
SM — low diagnostic (6) 5 (83.3%) 0 1 (16.7%)
SM (62) 29 (46.8%) 3 (4.8%) 30 (48.4%)
32 (51.6%)
*after exclusion of 7 cases of SM-pap-low risk of malignancy; ap < 0.0001 vs. FLUS, SFN, FLUS/FLUS-O, SFN/SFN-O; bp < 0.0005 vs. SFN-O. FLUS — follicular lesion of 
undetermined significance; FNA — fine-needle aspiration; SFN — suspicious for follicular neoplasm; SM — suspicious for malignancy
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higher risk —SM-pap (the patient has not been oper-
ated yet) (Table II). Considering nodules followed up 
histopathologically or cytologically, thyroid cancers 
were diagnosed in 2 out of 16 (12.5%) SM-low diag-
nostic nodules. 
No significant differences in the size of nodules 
were found between benign lesions and cancers in 
particular subgroups of ISC nodules (mean volume 
± SD in all ISC — 6.4 ± 12.2 vs. 5.0 ± 4.8 cm3), and in 
each subgroup the mean volume of cancers was slightly 
lower than that of benign nodules. No significant dif-
ferences were found in the mean age of the patients 
with cancers and benign nodules (mean age ± SD of 
the ISC group for cancers and benign nodules: 53.5 ± 
± 16.2 vs. 53.0 ± 13.5 years, respectively). Noticeable 
differences were observed only in the SFN/SFN-O group 
(respectively, 47.7 ± 17.7 vs. 53.0 ± 13.5 years, NS). The 
percentages of males with cancer and benign nodule 
were also similar in ISC nodules: 13.3% vs. 11.1%, and 
the most visible differences were in the SFN/SFN-O 
group: 20.0% vs. 12.9% (NS).
Table V shows ultrasonographic characteristics data 
of the nodules of examined ISC subgroups in relation 
to the category of final histopathological diagnosis. 
Multivariate analysis of regression indicated that the 
only independent factor pointing to malignancy in an 
Table V. Characteristics of ultrasonographic images in particular ISC categories in relation to the results of postoperative 
histopathological examination (the nodules without full data on ultrasonographic examination were excluded) 
Tabela V. Charakterystyka obrazu ultrasonograficznego w poszczególnych kategoriach ISC z uwzględnieniem wyników 
pooperacyjnego badania histopatologicznego (wyłączono guzki z brakiem pełnych danych z badania US) 
Sonographic feature FLUS/FLUS-O 189 SFN/SFN-O
111
SM
51
ISC
351
ISC group 
OR (95% Cl)
p value
B
177 
M
12
B
101
M
10
B
28
M
23
B
306
M
45
Univariate 
analysis
Multivariate 
analysis
Solid hypoechoic 88
49.7%
8
66.7%
63
62.4%
6
60.0%
10
35.7%
12
52.2%
161
52.6%
26
57.8%
1.2 (0.7–2.3)
0.517
1.2 (0.6–2.3)
0.624
Taller-than-wide shape 17
9.6%
3
25.0%
16
15.8%
2
20.0%
6
21.4%
6
26.1%
39
12.7%
11
24.4%a
2.2 (1.0–4.7)
0.039
1.8 (0.8–4.1)
0.166
Pathological 
vascularisation
35
19.8%
4
33.3%
25
24.8%
2
20.0%
5
17.9%
3
13.0%
65
21.2%
9
20.0%
0.8 (0.4–0.9)
0.810
0.9 (0.4–2.1)
0.844
Suspicious margin 17
9.6%
1
8.3%
10
9.9%
0
0.0%
5
21.4%
7
30.4%
32
10.5%
8
17.8%
1.9 (0.8–4.3)
0.154
1.2 (0.5–3.1)
0.671
Calcifications (micro 
or macro or rim type 
calcifications)
16
9.0%
4
33.3%b
16
15.8%
4
40.0%
6
21.4%
10
43.5%
38
12.4%
18
40.0%c
4.7 (2.4–9.4)
0.000
4.1 (1.8–9.6)
0.000
Microcalcifications 6
3.4%
1
8.3%
7
6.9%
1
10.0%
1
3.6%
5
21.7%
14
4.6%
7
15.6%d
3.8 (1.5–10.2)
0.006
1.1 (0.3–3.6)
0.882
SEN SPC PPV NPV
 > 1 UMRFs 44
24.9%
5
41.7%
37
36.6%
5
50.0%
6
21.4%
10
43.5%
87
28.4%
20
44.4%a
44.4 71.6 18.7 89.8
Taller-than-wide shape 
or calcifications
16
9.0%
4
33.3%b
16
18.8%
4
40.0%
9
32.1%
11
47.8%
41
13.4%
19
42.2%c
42.2 86.6 31.7 91.1
Solid hypoechoic 
nodule with: taller-
than-wide shape or 
suspicious margin or 
microcalcifications
22
12.4%
3
25.0%
17
16.8%
1
10.0%
4
14.3%
9
39.1%e*
43
14.1%
13
28.9%a
28.9 85.9 23.2 89.2
Taller-than-wide shape 
or suspicious margin or 
calcifications
41
23.2%
5
41.7%
30
29.7%
5
50.0%
12
42.9%
13
56.6%
83
27.1%
23
51.1%d
51.12 72.9 21.7 91.0
ap < 0.05 M vs. B in ISC group; bp < 0.05 M vs. B in FLUS/FLUS-O group; cp < 0.0001 M vs. B in ISC group; dp < 0.005 M vs. B in ISC group; ep < 0.0886 M vs. B in 
SM group (*when calcifications were considered p < 0.05). FLUS — follicular lesion of undetermined significance; ISC — indeterminate, suspicious cytology; NPV — negative 
predictive value; PPV — positive predictive value; SEN — sensitivity; SFN — suspicious for follicular neoplasm; SM — suspicious for malignancy; SPEC — specificity
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ISC nodule was the presence of calcifications (OR 4.1). 
That feature was present in 33.3% to 43.5% of cancers in 
particular ISC subgroups and was the only independ-
ent malignancy risk factor in the FLUS/FLUS-O sub-
group (OR 8.5, 95% CI 1.7–42.4, p < 0.01). Univariate 
analysis of regression suggested that suspicious shape 
(OR 2.2) and microcalcifications (OR 3.8) might also be 
useful predictors of malignancy. However, the detailed 
analysis in the subgroups indicated their low SEN (sus-
picious shape — 20–26% in the particular subgroups, 
microcalcifications — 21.7% in SM subgroup, and 
in FLUS/FLUS-O and SFN/SFN-O subgroups — not 
exceeding 10%). The presence of suspicious margins 
was rare in the cancers in the FLUS/FLUS-O and SFN/ 
/SFN-O groups (< 5%), and in the SM group it reached 
30%, but this feature was also present in 21.4% of be-
nign nodules in that subgroup. Hypoechogenicity was 
observed with similar frequency in cancers and benign 
nodules of the SFN/SFN-O group (60.0% vs. 62.4%). In 
the other subgroups that feature dominated in can-
cers but without reaching the border of significance. 
Internal vascularisation had no diagnostic meaning 
in any ISC subgroup, and in the SFN/SFN-O and SM 
subgroups it was even less frequent in cancers than in 
benign lesions.
Analysis of the presence of at least two of any UM-
RFs (which was also a significant factor according to 
the univariate logistic regression analysis: OR 2.0, 95% 
CI 1.1–3.8, p < 0.05) did not significantly increase SEN 
in comparison to the evaluation of calcifications only 
(Table V). The limitation of the features in the analysed 
set to calcifications and suspicious shape only (OR 4.7, 
95% CI 2.4–9.3, p < 0.0001) increased PPV, but not SEN. 
When the set of features recommended by the ATA 
(hypoechoic nodule with suspicious shape or suspicious 
margins or microcalcifications) (OR 1.8, 95% CI 1.3–2.6, 
p < 0.0001) was applied the SEN dropped to 28.9% be-
cause of its insufficiency in the SFN/SFN-O (SEN 10%) and 
FLUS/FLUS-O (SEN 25%) subgroups. Better results could 
be obtained with the set of features based on the pres-
ence of any single feature from those recommended by 
the ATA independently on echogenicity of the nodule 
and including all calcifications and not only microcal-
cifications (OR 2.8, 95% CI 1.5–5.3, p < 0.001) (SEN for 
FLUS/FLUS-O — 41.7%, for SFN/SFN-O 50%, and for 
SM — 56.6%). 
Table VI shows a comparison of the FLUS/FLUS-
O nodules’ volume and the incidence of UMRFs in 
those nodules in relation to the applied procedures 
after first FNA, i.e. rFNA vs. surgery. It was found that 
the mean volume of FLUS nodules operated directly 
after first FNA was higher than that of the nodules 
subjected to rFNA (6.8 ± 12.8 vs. 3.9 ± 11.6 cm3, 
p < 0.05). On the other hand, the nodules subjected to 
rFNA more frequently showed calcifications (18.5% vs. 
7.6%, p < 0.005). The incidence of other UMRFs was 
similar. The mean age of the patients with FLUS nodule 
treated surgically was lower than that of the patients 
subjected to rFNA (51.2 ± 12.4 vs. 60.0 ± 12.8, p < 0.0001). 
Discussion
Analysis of the clinical significance of equivocal results of 
fine-needle aspiration biopsy of the thyroid is subjected 
to several objective difficulties. The results of such analy-
ses are variable also because they markedly depend on 
the methodological factors. The mentioned difficulties 
and factors modify the frequency of particular sub-
groups among ISC nodules and the risk of malignancy 
related to each subgroup. They also make the data from 
various centres hardly comparable. The objective dif-
ficulties include epidemiological differences between 
examined populations, usually occurring due to differ-
ent iodine supply. It modifies a priori risk of malignancy 
in thyroid nodules and changes the relative frequency 
of papillary and follicular cancers [18]. In consequence, 
Table VI. Characteristics of ultrasonographic image of FLUS 
nodules subjected to repeat FNA or to surgical treatment 
without control cytological examination
Tabela VI. Charakterystyka obrazu ultrasonograficznego 
guzków FLUS poddawanych powtórnym FNA i kierowanych 
na leczenie operacyjne bez kontrolnej cytologii
Sonographic feature Decision after first FNA
(number/% of nodules)
Repeat FNA
271
Surgery
157*
Solid hypoechoic 139
51.3%
76
48.4%
Taller-than-wide shape 37
13.7%
15
9.6%
Pathological vascularisation 45
16.6%
29
18.5%
Suspicious margin 36
13.3%
12
7.6%
Calcifications 50
18.5%
12
7.6%a
Microcalcifications 18
6.6%
4
2.5%
 > 1 URFs 80
29.5%
36
22.9%
Mean volume ± SD 3.9 ± 11.6 6.8 ± 12.8b
*the nodules without full data on ultrasonographic examination were excluded; 
ap < 0.005 surgery vs. Rfna; bp < 0.05 surgery vs. rFNA. FNA — fine-needle 
aspiration
31
Endokrynologia Polska 2016; 67 (1)
PR
A
C
E 
O
RY
G
IN
A
LN
E
it influences the distribution of the subcategories of ISC 
nodules and affects values of variables describing FNA 
effectiveness, that are the lower, the higher is the per-
centage of FL nodules (because of the limitations of FNA 
in distinguishing their types) is higher [1, 17]. Another 
difficulty is the heterogeneity of FLUS category. These 
diagnoses are formulated usually by exclusion of other 
diagnostic categories and are not a consequence of the 
presence of specific features in a smear [4–5, 19]. Thus, 
they are more prone to interobserver discrepancies [13, 
20–21]. A particularly controversial problem is the degree 
of nuclear atypia (polymorphism) that allows the catego-
risation of aspirate as FLUS and not SM. Some authors 
even distinguish the separate category for smears with 
abnormalities in cellular nuclei, such as the presence 
of occasional nuclear grooves, an abnormal chromatin 
pattern, or nuclear overlapping and crowding [7–11, 22].. 
These findings concern the presence of a papillary thy-
roid carcinoma. Choi et al. (2014) named that subgroup 
– “AUS - atypia with undetermined significance”; Ho et 
al. applied the term “AUS/FLUS – cannot rule out PTC” 
[11, 23]. Rosario defined AUS as cytology demonstrating 
nuclear atypia, but not diagnostic of suspicious for ma-
lignancy or malignant tumour [12]. The next subgroup is 
intended to include smears that showed predominantly 
microfollicular pattern with low cellularity and no or 
minimal colloid – this subgroup is proposed to be still 
referred to as “FLUS” [11, 12, 22]. These should be fol-
licular nodules in which a distinction between follicular 
neoplasm and a hypercellular hyperplastic nodule is not 
possible. Our material included several cases of FLUS 
that could satisfy the criteria for AUS. It also included 
a dozen low-cellularity smears with single nuclear fea-
tures of papillary cancer for which the pathologist for-
mulated the recommendation to repeat FNA in a short 
time (earlier than recommended for FLUS nodules) and 
did not supply any additional conclusion. Those smears 
showed characteristics between SM and ND categories 
and in consequence were classified in the analysis as 
SM-low diagnostic. Because of the aforementioned fac-
tors the FLUS diagnosis constitutes, according to various 
authors, between 1% up to nearly 20% of all results [9, 19, 
24–34].. In our material these diagnoses are formulated 
in 4–5% of the patients each year, i.e. with the frequency 
assumed by the creators of this diagnostic category. As 
was shown in our earlier study, the introduction of FLUS 
diagnosis did not cause any significant change in the 
total number of the results corresponding to FL, but it 
decreased the frequency of SFN diagnosis [17].
Other problems related to analysis of clinical sig-
nificance of ISC results are the consequence of draw-
ing conclusions on the risk of malignancy in a nodule 
directly from the incidence of cancer in postoperative 
histopathological examination, as is done by some au-
thors. In such circumstances the error is greater, the less 
obvious indications are for surgical treatment connected 
to the analysed FNA diagnosis category. In the case 
of nodules with lower risk of malignancy the surgical 
treatment is mainly performed in patients with clinical 
risk factors for malignancy. It can be rationally assumed 
that in non-operated nodules the actual risk of cancer is 
lower, but it is hardly assessable on the basis of clinical 
follow-up only. The other difficulty that limits possi-
bilities of comparison of the published data is various 
reference levels of the diagnostic centres. Some reports 
come from consultation centres that deal mainly with 
especially suspicious and difficult for interpretation 
nodules, which can falsely increase the observed inci-
dence of cancers in a diagnostic category. Also of high 
importance is the lack of precise information on exclu-
sion from the analysis of the cancers revealed in nodules 
other than those examined cytologically — such cancers 
are usually incidentalomas. Sometimes such exclu-
sion is difficult to perform, when there are numerous 
nodules in the thyroid and it is difficult to precisely 
identify in which of the nodules described in an ul-
trasonographic report the cancer has been diagnosed. 
As a consequence of the above-mentioned factors the 
risk of malignancy in FLUS nodules as assessed on the 
basis of postoperative histopathological examination 
ranges from 4% up to as much as 50% [12, 22–28, 30–41], 
so it exceeds by several times the values suggested by 
NCI recommendations. Many authors indicate that the 
final malignancy results were observed several times 
more frequently in AUS than in FLUS [7–14]. In our 
material, in 1 of 3 cases of FLUS with features of nuclear 
atypia a papillary cancer was found in postoperative 
examination. Such low numbers make it difficult to 
draw any conclusions on the risk of cancer in such cases. 
However, the low frequency of such aspirates in our ma-
terial is noticeable, especially in comparison with some 
reports describing 10-fold higher frequencies [24, 26]. It 
can be explained by epidemiological circumstances and 
still high incidence of non-neoplastic thyroid nodules in 
our patients. But it can also be a consequence of more 
conservative attitude to the rules for formulation of 
FLUS diagnosis, which was limited to nodules from 
the boundary between follicular neoplasms and benign 
lesions. As a result, the percentage of cancers revealed 
in FLUS nodules is low at our centre. 
As a consequence of different frequencies of can-
cers diagnosed in FLUS nodules there are variable 
recommendations on optimal procedures in the case 
of FLUS. Our data give a rationale for performing 
rFNA. According to our analysis, it allows more pre-
cise diagnosis in more than 70% of cases (and about 
64% after first rFNA). Similar data on the efficacy 
of repeat FNA were shown by Sullivan et al., who 
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reported that repeat FNA reclassified 56% of AUS/ 
/FLUS cases into a definitive category [42]. It should 
be mentioned that rFNA allowed malignant nodules 
to be revealed in our material. Similarly, Faquin and 
Baloch showed higher frequency of revealing cancer 
in a group of patients operated after repeat FNA 
than in patients operated directly after obtaining 
FLUS diagnosis [26]. There are, however, conflicting 
reports [23, 30, 32].
According to various studies, including our data, in 
the case of 30% of FLUS nodules rFNA corresponds to 
the same category again or it does not bring diagnostic 
material [23, 26, 30, 39–40]. In some other analyses this 
percentage reaches half of the cases [12, 43]. Some au-
thors believe that the risk of malignancy in nodules with 
double FLUS diagnosis is higher than in nodules with 
single FLUS result [12, 39, 42]. Our data did not confirm 
the increased risk of malignancy in such cases, but the 
AUS subcategory was not assigned in any of them. It 
is still debatable how to deal with two FLUS diagnoses. 
It seems reasonable to think primarily of surgical treat-
ment if the cytological picture corresponds to the AUS 
subcategory. An additional factor speaking in favour of 
thyroidectomy may be a suspicious ultrasonographic 
image of the nodule [12, 43], but some authors did not 
confirm such conclusions [44]. Currently, molecular 
studies may be proposed to resolve diagnostic doubts 
related to ISC nodules (as a replacement for the repeat 
cytology or as an additional tool), but the results of such 
methods are still unsatisfactory [15] and the availability 
of such techniques is limited. 
There are also controversies relating to the situation 
when the result of rFNA corresponds to a benign lesion. 
In our material there was no cancer in such patients. 
Similarly, Faquin and Baloch reported that no case was 
finally confirmed as malignancy among nodules with 
initial FLUS cytology result and benign result in repeat 
FNA [26]. Other authors did not observe an increased 
risk of cancer in such cases, and they concluded that 
clinical follow-up instead of surgical excision or con-
tinuous repeat FNA may be enough for benign thyroid 
nodules after FLUS [45]. On the other hand, it was re-
ported in some studies that malignancy risk was higher 
in patients with benign cytology results after an initial 
ISC or AUS/FLUS when compared with single benign 
diagnoses [42, 46]. Undoubtedly this problem needs 
further investigation.
Some authors indicate that the frequency of cancer 
is higher in oxyphilic type of FLUS [47]. Others do 
not support such observations [13–14]. In our mate-
rial FLUS-O diagnoses were rarely formulated (2.5% 
of all FLUS), and only six nodules were verified with 
histopathological examination that revealed one 
cancer (16.7%). It is difficult to draw any conclusions 
on increased risk of malignancy from such data. In-
terestingly, SFN-O diagnoses constituted more than 
a half of all SFN cases. In that case the incidence of 
cancer in histopathological examination was 10.5% 
for SFN-O and 6.2% for SFN, but the difference was 
insignificant.
Another problem is related to differences in malig-
nancy risk between FLUS and SFN categories. Faquin 
and Baloch found that risk as assessed by histopatholog-
ical examination to be similar for both those diagnoses 
[26], and as reported by Theoharis et al. the incidence 
of cancers was higher in the FLUS group — 48% than 
in the SFN group — 34% [24]. Other authors indicate 
that the FLUS category — according to the assumptions 
– should select from FL the nodules with lower risk of 
malignancy: Wu et al. — incidence of cancer in FLUS 
nodules — 6%, SFN — 22%, Bongiovanni et al. — 14.4% 
and 32.1%, respectively, Iskander et al. — 13% and 28%, 
respectively [25, 31, 36]. In our material the difference 
in the incidence of cancer in postoperative examination 
of FLUS and SFN nodules was smaller (5.9% vs. 8.2%), 
but if non-operated nodules had been also considered, 
the risk of malignancy in FLUS nodules would have 
been three times lower than that in SFN nodules (2.4% 
and 7.4%, respectively). Considering these data it can 
be stated that in our centre FLUS category satisfied ex-
pectations for selection of low malignancy risk nodules 
from all follicular lesions. 
The last question to discuss is the usefulness of 
UMRFs analysis in making clinical decisions in pa-
tients with FLUS nodules. In our previous study we 
reported that FLUS nodules showed US features of 
intermediate values between BL and SFN nodules 
[16]. In the present study the frequency of particular 
UMRFs in ISC nodules was evaluated in relation to 
the final histopathological examination. We found 
that the only independent feature of malignancy in 
FLUS nodules was the presence of calcifications of any 
type. In all ISC nodules, apart from calcifications of all 
types, suspicious shape and microcalcifications were 
also significant features. However, the application of 
the criteria based on the set of those features (calcifica-
tions or suspicious shape) or the presence of at least 
two UMRFs or the features proposed by the ATA as a 
criterion of high risk of malignancy, shows low SEN in 
ISC nodules. More than half of cancers were found in 
FLUS nodules that did not satisfy those criteria. Cuhaci 
et al. also found that ultrasonographic features alone 
may be insufficient to predict the malignancy of FLUS 
nodules [22]. According to their data the predictive 
features of malignancy are hypoechogenicity and 
peripheral vascularisation of the nodule. Similarly, 
Iskandar et al. did not confirm the usefulness of ul-
trasonographic features in predicting malignancy of 
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FLUS nodule. They did not find gender nor nodule 
size to be useful either, and only age < 30 years was 
associated with an increased risk of malignancy of 
FLUS [36]. In our study gender, age, and nodule size 
did not prove to be useful in the prediction of malig-
nancy of ISC nodules, and especially FLUS nodules. 
It should be mentioned that there are also conflicting 
reports on the role of UMRFs in patients with ISC. 
Yoo et al. showed that independent features speak-
ing in favour of malignancy of FLUS nodule included 
taller-than-wide shape, marked hypoechogenicity, and 
ill-defined margin [48]. According to their analysis 
two former features showed very high PPV, and the 
authors concluded that those features should be re-
garded as highly suspicious US findings that should 
suggest surgical treatment instead of repeat cytology. 
Rosario et al. also reported that analysis of UMRFs 
was important for making therapeutic decisions in 
patients with FLUS nodules [12]. Summing up, the 
data on the usefulness of UMRF assessment in making 
clinical decisions on FLUS nodules are still unsatisfac-
tory. This could be a consequence of the diversity of 
the examined populations, different frequencies of 
particular types of thyroid cancers in the examined 
groups, different size of these groups, and various 
proportions of benign and malignant nodules. The 
large meta-analysis by Remonti et al. [49] was an at-
tempt to summarise analyses published so far. The 
authors drew the conclusion that in the subgroup of 
nodules with indeterminate cytology any of the US 
features was sufficient to determinate the risk of malig-
nancy with an acceptable SEN [49]. It seems that such 
a view is shared by the majority of clinicians because, 
as indicated by our data and other published reports, 
they tended to refer for surgical treatment younger 
patients or those with larger nodules, but not those 
with suspicious US image [23, 50].
Conclusions
It should be stressed that the attempt to unify the 
method of diagnosis formulation in the case of follicular 
lesions of the thyroid has not been successful. Such con-
sistent diagnoses are a key demand for making studies 
from different centres comparable. They are also neces-
sary in order to elaborate common recommendations. 
Currently, it is still important to analyse one’s own ex-
perience in relation to the risk of cancer in ISC nodules. 
At our centre the risk of malignancy in FLUS and SFN 
nodules is visibly lower than in SM nodules. The FLUS 
category allows the selection from ISC of the nodules 
with lower risk of malignancy, which should be followed 
by rFNA. The repeat FNA of FLUS nodules allows the 
formulation of more precise diagnosis in more than 70% 
of cases and is effective in revealing cancers. Analysis of 
UMRFs has a variable diagnostic value depending on the 
ISC subcategory. It may be an additional aid for making 
therapeutic decisions, but sole evaluation of UMRFs is 
insufficient for drawing clinical conclusions. 
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